BMP and Other Activin Receptor Inhibitors Products
Cellular responses to bone morphogenetic proteins (BMPs) are mediated by the formation of hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. There are seven known type I serine/threonine kinases and five mammalian type II serine/threonine kinase receptors that function in TGF-beta superfamily signal transduction. The type II receptors for TGF-beta and activin bind ligands with high affinity by themselves. In contrast, BMPR-II binding to BMP-2, BMP-4, and BMP-7 is facilitated by the presence of the type I receptor. The type I receptors are also known as activin receptor-like kinases or ALKs.
10 results for "BMP and Other Activin Receptor Inhibitors" in Products
10 results for "BMP and Other Activin Receptor Inhibitors" in Products
BMP and Other Activin Receptor Inhibitors Products
Cellular responses to bone morphogenetic proteins (BMPs) are mediated by the formation of hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. There are seven known type I serine/threonine kinases and five mammalian type II serine/threonine kinase receptors that function in TGF-beta superfamily signal transduction. The type II receptors for TGF-beta and activin bind ligands with high affinity by themselves. In contrast, BMPR-II binding to BMP-2, BMP-4, and BMP-7 is facilitated by the presence of the type I receptor. The type I receptors are also known as activin receptor-like kinases or ALKs.
Selective inhibitor of TGF-βRI, ALK4 and ALK7
| Chemical Name: | 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide |
| Purity: | ≥98% (HPLC) |
Potent AMPK inhibitor; also BMP type I receptor inhibitor
| Alternate Names: | Compound C,BML-275 |
| Chemical Name: | 6-[4-[2-(1-Piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidine dihydrochloride |
| Purity: | ≥98% (HPLC) |
Potent and selective ALK2 and ALK3 inhibitor; inhibits BMP4 signaling; promotes neural induction of hPSCs
| Chemical Name: | 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride |
| Purity: | ≥98% |
Selective ALK2 inhibitor
| Chemical Name: | 4-[6-[4-(1-Methylethoxy)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline |
| Purity: | ≥98% (HPLC) |
Type I BMP receptor inhibitor
| Chemical Name: | 4-[6-[4-[2-(4-Morpholinyl)ethoxy]phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline |
| Purity: | ≥98% (HPLC) |
Type 1 BMP receptor inhibitor
| Chemical Name: | 3-[(6-Amino-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenol |
| Purity: | ≥99% |
Selective inhibitor of TGF-βRI, ALK4 and ALK7
| Chemical Name: | 2-[4-(1,3-Benzodioxol-5-yl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-6-methyl-pyridine |
| Purity: | ≥98% (HPLC) |
A 83-01 synthesized to Ancillary Material Grade
| Chemical Name: | 3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide |
| Purity: | ≥98% |
Potent and selective ALK1 and ALK2 inhibitor
| Alternate Names: | LDN 193719,1lWY,VU0469381 |
| Chemical Name: | 5-[6-(4-Methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline |
| Purity: | ≥98% (HPLC) |
Sterile-filtered 10 mM solution of LDN 193189 pre-dissolved in water
| Chemical Name: | 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline dihydrochloride |
| Purity: | ≥97% (HPLC) |
